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Abstract
The aim of this study was to evaluate the ability of 4 risk-of-malignancy indexes (RMIs) to discriminate benign
from malignant pelvic masses. The RMI methods were calculated for 296 patients together with the sensitivity,
speciﬁcity, positive predictive value, and negative predictive value. The RMI method is a valuable and appli-
cable method in diagnosing pelvic masses with high risk of malignancy.
Background: The aim of this study was to validate the risk-of-malignancy index (RMI) incorporating menopausal
status, serum CA 125 levels, and imaging ﬁndings for discriminating benign from malignant pelvic masses and to
evaluate the ability of 4 different RMIs. Patients and Methods: This is a prospective study of 296 women admitted to
the Department of Obstetrics and Gynecology of Kochi Health Sciences Center, between September 2011 and April
2014, for surgical exploration of pelvic masses. The RMI 1, 2, 3, and 4 methods were calculated for all patients
together with the sensitivity, speciﬁcity, positive predictive value, and negative predictive value. Results: The sensi-
tivity of RMIs 1, 2, 3, and 4 was 73.0%, 81.1%, 73.0%, and 77.0%, respectively, and the speciﬁcity was 93.7%,
89.6%, 93.7%, and 92.3%, respectively. The RMI 2 was signiﬁcantly better at predicting malignancy than RMIs 1 3;
however, there was no statistically signiﬁcant difference in performance of RMIs 2 4. Conclusion: The RMI method is a
valuable and applicable method in diagnosing pelvic masses with high risk of malignancy and a simple technique that
can be used in gynecology clinics and less-specialized centers.
Clinical Ovarian and Other Gynecologic Cancer, Vol. 7, No. 1/2, 8-12 ª 2015 Elsevier Inc. All rights reserved.
Keywords: Imaging score, Menopausal status, Ovarian cancer, Serum CA 125 level, Simple techniqueIntroduction
A pelvic mass is one of the most frequent indications for referral
to gynecology specialists. Often, these pelvic masses are malignant
and require surgical treatment. Up to 24% of ovarian tumors in
premenopausal women are malignant and up to 60% are malignant
in postmenopausal women.1-3
The preoperative determination of whether a mass is malignant
cannot always be made with current diagnostic modalities. Surgery
can be optimally planned if it is known in advance whether anDepartment of Obstetrics and Gynecology, Kochi Health Sciences Center, Kochi,
Kochi, Japan
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nical Ovarian and Other Gynecologic Cancer December 2014ovarian neoplasm is benign or malignant. The type of surgical
procedure and the experience of the surgeon are important factors
for the prognosis of ovarian cancer. An improved method for pre-
operative discrimination of pelvic mass would result in more women
receiving ﬁrst-line therapy from appropriately trained and experi-
enced personnel.4,5 For such referrals to be efﬁcient, improved
speciﬁc and sensitive methods for diagnosing ovarian cancer are
needed.
Used alone, the diagnostic accuracy of demographics,
ultrasound (US), and biochemical variables is inadequate for
clinical application. Various combined methods for evaluating
the risk of ovarian cancer have been proposed. The risk-
of-malignancy index (RMI) is a simple scoring method based
on menopausal status, US ﬁndings, and the serum CA 125
level. This method has given signiﬁcantly better results than
the use of a single parameter.6-8 The RMI can be applied in
less-specialized centers. The RMI is the product of the imaging2212-9553/$ - see frontmatter ª 2015 Elsevier Inc. All rights reserved.
http://dx.doi.org/10.1016/j.cogc.2014.11.001
scores (U), the menopausal score (M), and the absolute value of
the serum CA 125:
RMI ¼ U  M  CA 125
In 1990, Jacobs et al6 originally developed the RMI, which we
have termed “RMI 1.” Tingulstad et al7 developed their version of
the RMI in 1996, and it is known as RMI 2. In1999, Tingulstad
et al8 modiﬁed the RMI, which we have termed “RMI 3.” In 2009,
Yamamoto et al9 added the parameter of the tumor size score (S) to
the RMI and have termed it the RMI 4:
RMI 4 ¼ U  M  S  CA 125
The aim of this study was to evaluate the ability of 4 RMI to
discriminate a benign from a malignant pelvic mass and to evaluate
the performances of 4 RMI.
Patients and Methods
This is a prospective study. The clinical data were obtained
from 296 women with a pelvic mass scheduled for laparotomy and
laparoscopy at the Department of Obstetrics and Gynecology of
Kochi Health Sciences Center between September 1, 2011, and
April 30, 2014. Preoperative serum CA 125 levels, imagingTable 1 Distribution of Diagnosis and Stages in 296 Patients Prese
Diagnosis Premenopausal Patients
Ovarian cancer
Stage I 6 I, 9 B
Stage II 1 I, 2 B
Stage III 4 I, 1 B
Stage IV 1
Tubal cancer
Stage II 0
Stage III 0
Stage IV 0
Metastatic cancer 3
Total malignant cases 27
Endometriosis 68
Dermoid cyst 54
Serous cystadenoma 14
Mucinous cystadenoma 17
Parovian cyst 2
Fibroma/thecoma 1
Hydrosalpinx 3
Tubo-ovarian abscess 1
Leiomyoma 6
Other 7
Total benign cases 166a
Abbreviations: B ¼ borderline; I ¼ invasive.
aIncluding 2 cases of endometriosis þ dermoid cyst and endometriosis þ serous cystadenoma, s
mucinous cystadenoma.
bIncluding endometriosis þ serous cystadenoma, serous þ mucinous cystadenoma, and serous cy
cIncluding 3 cases of endometriosis þ serous cystadenoma, 2 cases of dermoid cyst þ endometriosi
mucinous cystadenoma, and serous cystadenoma þ ﬁbroma.ﬁndings, and menopausal status were noted. All patients were
required to have a pelvic US, computed tomography (CT), mag-
netic resonance imaging (MRI), or any combination of imaging
modalities for documentation of an ovarian tumor or a pelvic
mass. An RMI imaging score was assigned for the following fea-
tures suggestive of malignancy: the presence of a multilocular
cystic lesion; solid areas; bilateral lesions; ascites; and intra-
abdominal metastases. One point was given for each feature. A
total imaging score (U) was calculated for each patient, and the
tumor size (S) was measured by US, CT, and/or MRI for each
patient. Postmenopausal status was deﬁned as more than 1 year of
amenorrhea or age greater than 50 years in women who had un-
dergone hysterectomy. All other women were considered pre-
menopausal. Preoperative serum CA 125 levels were measured in
the hospital’s biochemistry laboratory by ECLusys CA125 II assay
(Roche Diagnostics, Tokyo, Japan).
On the basis of the data obtained, the RMI 1, 2, 3, and 4
methods were calculated for all patients together with the sensitivity,
speciﬁcity, positive predictive value, and negative predictive value of
the 4 methods:
(1) RMI 1 (Jacobs et al6) ¼ U  M  CA 125; a total US
score of 0 yielded U ¼ 0, a score of 1 yielded U ¼ 1, and a
score ofS 2 yielded U ¼ 3. Premenopausal status yielded
M ¼ 1 and postmenopausal status yielded M ¼ 3. Thenting With a Pelvic Mass
Postmenopausal Patients Total, Patients (%)
10 I, 7 B 16 I (5.4), 16 B (5.4)
3 4 I (1.4), 2 B (0.7)
15 19 I (6.4), 1 B (0.3)
3 4 (1.4)
1 1 (0.3)
2 2 (0.7)
1 1 (0.3)
5 8 (2.7)
47 74 (25.0)
3 71 (24.0)
7 61 (20.6)
18 32 (10.8)
15 22 (7.4)
4 6 (2.0)
8 9 (3.0)
0 3 (1.0)
2 3 (1.0)
0 6 (2.0)
2 9 (3.0)
56b 222c (75.0)
erous þ mucinous cystadenoma, dermoid cyst þ serous cystadenoma, and dermoid cyst þ
stadenoma þ ﬁbroma.
s and serous þ mucinous cystadenoma, dermoid cyst þ serous cystadenoma, dermoid cyst þ
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Table 2 Distribution of Age, Menopausal Status, Imaging Score, and Serum CA 125 Levels in 296 Women With Benign and Malignant
Pelvic Masses
Variable
Benign, n [ 222 (75.0%);
n (%)
Malignant, n [ 74
(25.0%); n (%) Score P
Age (years)
&30 43 (19.4) 5 (6.8) c2 <.01
31-40 62 (27.9) 9 (12.2)
41-50 56 (25.2) 9 (12.2)
S51 61 (27.5) 51 (68.9)
Menopausal status
Premenopausal 166 (74.8) 27 (36.5) c2 <.01
Postmenopausal 56 (25.2) 47 (63.5)
Imaging score
0 54 (24.3) 0 (0) c2 <.01
1 94 (42.3) 10 (13.5)
2-5 74 (33.3) 64 (86.5)
Tumor size
<7 cm 107 (48.2) 20 (27.0) c2 <.01
S7 cm 115 (51.8) 54 (73.0)
CA 125 (U/mL)
Mean 39.7 1379.8 U test <.01
Medium 18.8 285.3
Minimum 4.5 5.0
Maximum 674.0 25010.0
Table 3 Sensitivity, Speciﬁcity, Positive Predictive Value
(PPVs), and Negative Predictive Value (NPVs) for
Predicting Malignancy of 4 Risk-of-Malignancy In-
dexes (RMIs 1, 2, 3, and 4)
RMI
Sensitivity
(%)
Speciﬁcity
(%) PPV (%) NPV (%)
RMI 1 (cutoff: 200) 73.0 93.7 79.4 91.2
RMI 2 (cutoff: 200) 81.1 89.6 72.3 93.4
RMI 3 (cutoff: 200) 73.0 93.7 79.4 91.2
RMI 4 (cutoff: 450) 77.0 92.3 77.0 92.3
Comparison of 4 RMIs
10 -serum level of CA 125 was applied directly to the
calculation.
(2) RMI 2 (Tingulstad et al7) ¼ U  M  CA 125; a total US
score of 0 or 1 yielded U ¼ 1 and a score of S 2 yielded
U ¼ 4. Premenopausal status yielded M ¼ 1 and post-
menopausal status yielded M ¼ 4. The serum level of CA
125 was applied directly to the calculation.
(3) RMI 3 (Tingulstad et al8) ¼ U  M  CA 125; a total US
score of 0 or 1 yielded U ¼ 1 and a score of S 2 yielded
U ¼ 3. Premenopausal status yielded M ¼ 1 and post-
menopausal status yielded M ¼ 3. The serum CA 125 level
was applied directly to the calculation.
(4) RMI 4 ¼ U  M  S  CA 125, where a total US score of
0 or 1 yielded U ¼ 1 and a score of S 2 yielded U ¼ 4.
Premenopausal status yielded M ¼ 1 and postmenopausal
status yielded M ¼ 4. A tumor size (single greatest diameter)
of < 7 cm yielded S ¼ 1 and S 7 cm yielded S ¼ 2. The
serum level of CA 125 was applied directly to the
calculation.9
The histopathologic diagnosis was regarded as the deﬁnite
outcome. When a gynecological cancer was found, it was staged
according to the International Federation of Gynecology and
Obstetrics (FIGO) classiﬁcation.10 The sensitivity was deﬁned as
the percentage of patients with malignant disease having a positive
test result. The speciﬁcity was deﬁned as the percentage of pa-
tients with benign disease having a negative test result. The
positive predictive value was deﬁned as the percentage of patients
with a positive test result having malignant disease and theClinical Ovarian and Other Gynecologic Cancer December 2014negative predictive value was deﬁned as the percentage of patients
with a negative test result having benign disease. The c2 test was
used to test differences in distribution of age, menopausal status,
imaging score, and tumor size. The Mann-Whitney U test was
applied when testing differences in distribution of CA 125 among
women with benign and malignant pelvic masses. The McNemar
test was used when testing differences in performances between
RMIs 1, 2, 3, and 4.
Results
Of 296 patients, 74 (25.0%) had malignant disease and 222
(75.0%) had benign pathology. The mean age of the patients with
malignant disease was 56.3  15.7 years, and in those with benign
pathology, it was 43.6  15.4 years. The histopathologic classiﬁ-
cation of benign cases and FIGO10 stages of malignant cases were
detailed in Table 1.
Table 4 Sensitivity, Speciﬁcity, Positive Predictive Values
(PPVs), and Negative Predictive Values (NPVs) for
Predicting Malignancy of 4 Risk-of-Malignancy In-
dexes (RMIs 1, 2, 3, and 4)
RMI
Sensitivity
(%)
Speciﬁcity
(%) PPV (%) NPV (%)
RMI 1 (cutoff: 200) 92.9 88.6 57.4 98.7
RMI 2 (cutoff: 200) 97.6 83.5 49.4 99.5
RMI 3 (cutoff: 200) 92.9 88.6 57.4 98.7
RMI 4 (cutoff: 450) 95.2 86.6 54.1 99.1
Stage I disease is considered “benign” disease.
Yorito Yamamoto et alThe distribution of benign and malignant cases by age,
menopausal status, imaging score, and tumor size is described in
Table 2. In univariate analysis, a signiﬁcant linear trend for ma-
lignancy was found by increasing age, increasing imaging score,
and increasing tumor size. Signiﬁcantly, more postmenopausal
than premenopausal women had malignant disease. The mean
serum level of CA 125 was signiﬁcantly higher among women
with malignancy when compared with women who suffered from
a benign pelvic mass. The performance of RMIs 1, 2, 3, and 4
was presented in Table 3. A direct comparison of the 4 indexes
showed that RMI 2 was signiﬁcantly better at predicting malig-
nancy than RMIs 1 and 3 (P ¼ .04). There was no statistically
signiﬁcant difference in performance of RMIs 2 and 4. Because
the purpose of initial evaluation of the patients by RMI was to
ensure referral of patients with advance ovarian cancer, the results
were analyzed considering stage I disease a “benign” disease. The
results of the performance of RMIs 1, 2, 3, and 4 were presented
in Table 4.Table 5 False-Positive Cases and False-Negative Cases for Each of
RMI 1 (Cutoff: 200) RMI 2 (Cutoff: 200)
False-positive cases
Endometriosis 7 Endometriosis 12
Dermoid cyst 1 Dermoid cyst 1
Mucinous cystadenoma 2 Serous cystadenoma 1
Fibroma/thecoma 2 Mucinous cystadenoma 3
Tubo-ovarian abscess 1 Fibroma/thecoma 3
Leiomyoma 1 Tubo-ovarian abscess 1
Leiomyoma 1
Brenner tumor 1
False-negative cases
Borderline tumors
Stage I 10 Stage I 8
Stage II 1 Stage III 1
Stage III 1
Ovarian cancer
Stage I 7 Stage I 5
Stage III 1The false-positive and false-negative cases were listed in Table 5.
Up to 40% of the false-positive cases were endometriosis. The
false-negative cases were primarily borderline ovarian tumors
and stage I invasive ovarian cancers.
Discussion
This study has conﬁrmed the ability of 4 RMIs (RMIs 1, 2, 3,
and 4) to accurately discriminate between malignant and benign
pelvic masses. The RMI was originally developed by Jacobs et al,6
and subsequently, the same group reproduced the results in a sec-
ond patient population, establishing the superiority of the RMI over
the use of an individual parameter.11
Many authors suggest that the best cutoff value for RMIs 1, 2,
and 3 is 200.6-8,12,13 The best cutoff value for RMI 4 is 450.9
The sensitivity of RMIs 1, 2, 3, and 4 was 73.0%, 81.1%,
73.0%, and 77.0%, respectively. The speciﬁcity of RMIs 1, 2, 3,
and 4 was 93.7%, 89.6%, 93.7%, and 92.3%, respectively.
These are in accordance with the results of other studies.6-9,12-17
A direct comparison of the 4 indexes showed that RMI 2 was
signiﬁcantly better at predicting malignancy than RMIs 1 and 3
(P ¼ .04); however, there was no statistically signiﬁcant differ-
ence in performance of RMIs 2 and 4. The primary purpose of
initial evaluation of the patients by RMI was to ensure referral of
patients with advance ovarian cancer (greater than stage II) for
primary surgery at the gynecologic oncologic center. Our results
demonstrated that up to 95% were correctly identiﬁed before
treatment by RMIs 2 or 4 in Table 4. Otherwise, our results
demonstrated the limitation of RMI in identifying patients with
primarily borderline ovarian tumors and stage I invasive ovarian
cancers in Table 5.
In conclusion, the RMI is a simple scoring system, which can
be used in daily clinical practice in nonspecialized gynecologicthe 4 Risk-of-Malignancy Indexes (RMIs)
RMI 3 (Cutoff: 200) RMI 4 (Cutoff: 450)
Endometriosis 7 Endometriosis 8
Dermoid cyst 1 Dermoid cyst 1
Mucinous cystadenoma 2 Mucinous cystadenoma 3
Fibroma/thecoma 2 Fibroma/thecoma 3
Tubo-ovarian abscess 1 Tubo-ovarian abscess 1
Leiomyoma 1 Leiomyoma 1
Stage I 10 Stage I 9
Stage II 1 Stage III 1
Stage III 1
Stage I 7 Stage I 6
Stage III 1 Metastatic cancer
(breast cancer)
1
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Comparison of 4 RMIs
12 -departments by all gynecologists. We have not observed any
problems with the method in the participating departments.
This study has conﬁrmed the RMI to be a valuable and appli-
cable method in diagnosing pelvic masses with high risk of
malignancy and a workable method for the appropriate referral
of patients for specialized surgical treatment. Other models
of preoperative evaluation should be developed to improve
the detection of borderline ovarian tumors and stage I invasive
ovarian cancers.
Clinical Practice Points
 This study has conﬁrmed the ability of four malignancy risk
indices (RMI 1, RMI 2, RMI 3, and RMI 4) to accurately
discriminate between malignant and benign pelvic masses.
 The RMI is a simple scoring system which can be used in daily
clinical practice by all gynecologists. No problems with appli-
cation of the method were observed in the participating
departments.
 This study has conﬁrmed that an RMI can be a valuable and
applicable method in diagnosing pelvic masses with high risk of
malignancy, and is a workable method for appropriate and timely
referral of patients for specialized surgical treatment. It is our
impression that the use of an RMI has resulted in improved
preoperative planning from referral to actual performance of
surgery, as well as the planning of the surgical approach (lapa-
roscopy versus laparotomy, and transverse abdominal versus
median abdominal incision). Otherwise, this study results
demonstrate the limitations of RMI in identifying patients with
primarily borderline ovarian tumors and stage I invasive ovarian
cancers.
 Many cases of primarily borderline ovarian tumors and stage I
invasive ovarian cancers were false-negative. Other models of
preoperative evaluation should be developed in order to improve
the detection of borderline pelvic masses and ovarian tumors,
and detection of stage I invasive ovarian cancers.Clinical Ovarian and Other Gynecologic Cancer December 2014Disclosure
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